Mucoepidermoid Carcinoma in the Oropharynx: A Review of the Literature
G.A. Calcano,A.E. Brown,E.J. Moore,D.L. Price,K.K. Tasche,L.X. Yin,K.M. Van Abel
DOI: https://doi.org/10.1016/j.ijrobp.2024.01.181
IF: 8.013
2024-04-01
International Journal of Radiation Oncology*Biology*Physics
Abstract:Purpose/Objective(s) There is a lack of evidence-based recommendations for patient work up, counseling, and management of mucoepidermoid carcinoma of the oropharynx (OPMEC). We aim to perform a systematic review and summarize the demographics, clinical presentation, histology, treatment, and oncologic outcomes of OPMEC. Materials/Methods Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, and Daily, Ovid Ebase, Ovid Cochrane Central Register of Controlled Trials, and Scopus were searched for articles published through July 7, 2023. The search strategy was designed and conducted by a medical librarian following PRISMA guidelines. Review articles, national database studies, abstracts, and studies that did not report any of the outcomes of interest were excluded. The review was conducted by two independent reviewers (GAC and AEB) and conflicts were resolved by the senior author (KVA). Results A total of 23 publications were included with 76 patients. When reported, sex was predominantly female (27/51, 52%) with a mean age of 48 years (19 – 76). OPMEC was most common in the base of tongue (40/51, 78%) and most patients had an oropharynx mass on exam at presentation. Tumor stage was poorly documented but was frequently T1/2 when reported (25/37, 69%). Histological grade was most often reported as intermediate grade (31/70, 44%). There was a total of 32 patients with nodal involvement. One publication (n= 25) reported 68% (17/25) of patients who underwent neck dissection had pathologic lymph nodes. When pathologic lymph nodes were reported, the majority of tumors were intermediate grade (10/19, 52%). For only 26 patients, treatment was described. Among these, the primary treatment modality was surgery only (14/26, 53%) or surgery with adjuvant radiotherapy (9/26, 34%). Three additional patients were reported to receive chemotherapy during their treatment, but it is unclear if this was for primary treatment or recurrence. 55% (11/20) of final margins reported were positive. Follow-up length varied significantly (mean 35 months, range 0-146) and the overall survival was found to be 88% (range 0-100) at the time of publication, with two deaths not attributed to OPMEC and one likely attributed to OPMEC. Only one publication (n=26) included specific findings on survival outcomes, with 75% 5-year and 65% 10-year overall survival and 86% 5-year and 86% 10-year distant recurrence-free-survival. Conclusion The heterogeneity of studies highlights the lack of evidence supporting the understanding and management of OPMEC. OPMEC most often presents in middle aged females as a base of tongue mass and has a high potential for nodal metastasis, especially when the primary tumor is intermediate grade or higher. Oncologic outcomes appear to be fair following surgery with or without adjuvant therapy. However, further research is needed to develop an evidence-based treatment strategy for patients with OPMEC.
oncology,radiology, nuclear medicine & medical imaging